Search Results

There are 1259 results for: content related to: Managing Postmenopausal Women with Hormone Receptor–Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI 3K Pathway

  1. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

    Intervention Review

    The Cochrane Library

    Lorna Gibson, David Lawrence, Claire Dawson and Judith Bliss

    Published Online : 7 OCT 2009, DOI: 10.1002/14651858.CD003370.pub3

  2. Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant

    International Journal of Gynecological Cancer

    Volume 16, Issue s2, September 2006, Pages: 524–526, I. VERGOTE, F. AMANT, K. LEUNEN, T. VAN GORP, P. BERTELOOT and P. NEVEN

    Article first published online : 26 SEP 2006, DOI: 10.1111/j.1525-1438.2006.00687.x

  3. You have free access to this content
    Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer

    Cancer

    Volume 118, Issue 1, 1 January 2012, Pages: 241–247, Antonio Llombart-Cussac, Amparo Ruiz, Antonio Antón, Agustí Barnadas, Silvia Antolín, José E. Alés-Martínez, Isabel Álvarez, Raquel Andrés, José A. García Saenz, Juan Lao, Eva Carrasco, Carmen Cámara, Isabel Casas and Miguel Martín

    Article first published online : 29 JUN 2011, DOI: 10.1002/cncr.26299

  4. You have free access to this content
    Rational management of endocrine resistance in breast cancer

    Cancer

    Volume 113, Issue 9, 1 November 2008, Pages: 2385–2397, Sara A. Hurvitz and Richard J. Pietras

    Article first published online : 26 SEP 2008, DOI: 10.1002/cncr.23875

  5. Targeting Aromatase and Estrogen Signaling in Human Non-Small Cell Lung Cancer

    Annals of the New York Academy of Sciences

    Volume 1155, Issue 1, February 2009, Pages: 194–205, Diana C. Márquez-Garbán, Hsiao-Wang Chen, Lee Goodglick, Michael C. Fishbein and Richard J. Pietras

    Article first published online : 26 FEB 2009, DOI: 10.1111/j.1749-6632.2009.04116.x

  6. Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26–28, 2006

    International Journal of Gynecological Cancer

    Volume 16, Issue s2, September 2006, Pages: 479–491, P. NEVEN, I. VERGOTE, F. AMANT, P. BERTELOOT, E. De JONGE, C. DE ROP, P. DE SUTTER, A. MAKAR and J. VAN GINDERACHTER

    Article first published online : 26 SEP 2006, DOI: 10.1111/j.1525-1438.2006.00673.x

  7. Breast Cancer

    Standard Article

    Wiley Handbook of Current and Emerging Drug Therapies

    Published Online : 15 SEP 2006, DOI: 10.1002/9780470041000.cedt005

  8. You have free access to this content
    Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial

    Cancer

    Volume 119, Issue 10, 15 May 2013, Pages: 1908–1915, Howard A. Burris III, Fabienne Lebrun, Hope S. Rugo, J. Thaddeus Beck, Martine Piccart, Patrick Neven, Jose Baselga, Katarina Petrakova, Gabriel N. Hortobagyi, Anna Komorowski, Edmond Chouinard, Robyn Young, Michael Gnant, Kathleen I. Pritchard, Lee Bennett, Jean-Francois Ricci, Hounayda Bauly, Tetiana Taran, Tarek Sahmoud and Shinzaburo Noguchi

    Article first published online : 15 MAR 2013, DOI: 10.1002/cncr.28010

  9. Aromatase Inhibitors and Breast Cancer

    Annals of the New York Academy of Sciences

    Volume 1155, Issue 1, February 2009, Pages: 162–173, Luciana Furtado Macedo, Gauri Sabnis and Angela Brodie

    Article first published online : 26 FEB 2009, DOI: 10.1111/j.1749-6632.2008.03689.x

  10. You have full text access to this OnlineOpen article
    The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer

    International Journal of Clinical Practice

    Volume 61, Issue 12, December 2007, Pages: 2051–2063, C. J. Fabian

    Article first published online : 24 SEP 2007, DOI: 10.1111/j.1742-1241.2007.01587.x

  11. Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole

    The Journal of Clinical Pharmacology

    Volume 52, Issue 12, December 2012, Pages: 1852–1860, Dr Lauren Nicole Bell, Ms Anne Thi Phuong Nguyen, Dr Lang Li, Dr Zeruesenay Desta, Dr N. Lynn Henry, Dr Daniel F. Hayes, Dr Antonio C. Wolff, Dr Vered Stearns, Dr Anna Maria Storniolo and Dr David A. Flockhart

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011424153

  12. You have free access to this content
    Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

    Cancer

    Volume 98, Issue 2, 15 July 2003, Pages: 229–238, John F. R. Robertson, C. Kent Osborne, Anthony Howell, Stephen E. Jones, Louis Mauriac, Matthew Ellis, Ulrich R. Kleeberg, Steven E. Come, Ignace Vergote, Stan Gertler, Aman Buzdar, Alan Webster and Charles Morris

    Article first published online : 2 JUN 2003, DOI: 10.1002/cncr.11468

  13. You have free access to this content
    Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer

    CA: A Cancer Journal for Clinicians

    Volume 55, Issue 3, May/June 2005, Pages: 145–163, Dr. Ragini Kudachadkar and Dr. Ruth M. O'Regan

    Article first published online : 24 FEB 2009, DOI: 10.3322/canjclin.55.3.145

  14. You have full text access to this OnlineOpen article
    Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies

    International Journal of Cancer

    Volume 138, Issue 1, 1 January 2016, Pages: 146–159, Amit Agrawal, John F.R. Robertson, Kwok L. Cheung, Eleanor Gutteridge, Ian O. Ellis, Robert I. Nicholson and Julia M.W. Gee

    Article first published online : 30 JUL 2015, DOI: 10.1002/ijc.29682

  15. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery

    Journal of Pharmaceutical Sciences

    Volume 100, Issue 8, August 2011, Pages: 3208–3222, Raju Jukanti, Sruthi Sheela, Suresh Bandari and Prabhakar R. Veerareddy

    Article first published online : 14 MAR 2011, DOI: 10.1002/jps.22542

  16. You have free access to this content
    Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer

    Value in Health

    Volume 10, Issue 5, September/October 2007, Pages: 367–376, David Thompson, Douglas C. A. Taylor, Eduardo L. Montoya, Eric P. Winer, Stephen E. Jones and Milton C. Weinstein

    Article first published online : 16 JUN 2007, DOI: 10.1111/j.1524-4733.2007.00190.x

  17. Fulvestrant in Advanced Breast Cancer Following Tamoxifen and Aromatase Inhibition: A Single Center Experience

    The Breast Journal

    Volume 15, Issue 3, May/June 2009, Pages: 247–253, Jayson Wang, Sandeep Jain, Charles R. Coombes and Carlo Palmieri

    Article first published online : 5 MAY 2009, DOI: 10.1111/j.1524-4741.2009.00713.x

  18. You have free access to this content
    Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

    International Journal of Cancer

    Volume 126, Issue 2, 15 January 2010, Pages: 545–562, Sandra E. Ghayad, Julie A. Vendrell, Sabrina Ben Larbi, Charles Dumontet, Ivan Bieche and Pascale A. Cohen

    Article first published online : 16 JUL 2009, DOI: 10.1002/ijc.24750

  19. Is fulvestrant (“Faslodex”) just another selective estrogen receptor modulator?

    International Journal of Gynecological Cancer

    Volume 16, Issue s2, September 2006, Pages: 521–523, A. HOWELL

    Article first published online : 26 SEP 2006, DOI: 10.1111/j.1525-1438.2006.00686.x

  20. Impaired reproduction in adult male, but not female, rats following juvenile treatment with the aromatase inhibitor, exemestane

    Birth Defects Research Part B: Developmental and Reproductive Toxicology

    Volume 92, Issue 4, August 2011, Pages: 304–313, Gregg D. Cappon, Robert E. Chapin, Mark E. Hurtt, Michael P. Wajnrajch and Leigh Ann Burns-Naas

    Article first published online : 15 JUN 2011, DOI: 10.1002/bdrb.20307